---
layout: default
title: Secnidazole
parent: Model Prediction Only (L5)
nav_order: 1148
evidence_level: L5
indication_count: 7
---

# Secnidazole
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **7** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Secnidazole: From Antimicrobial Use (Anaerobic and Protozoal Infections) to Postmenopausal Atrophic Vaginitis

## One-Sentence Summary

Secnidazole is a 5-nitroimidazole antimicrobial marketed in the US as Solosec oral granules.
The TxGNN model predicts it may be effective for **postmenopausal atrophic vaginitis**, but there are **0 clinical trials** and **0 publications** supporting this direction. This is a model-only prediction, and no plausible mechanism has been identified.

---

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Postmenopausal atrophic vaginitis |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 |
| US Market Status | Marketed |
| Number of NDAs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the DrugBank extract. Secnidazole is a 5-nitroimidazole antimicrobial. Its nitro group is reduced under anaerobic conditions to radicals that damage microbial DNA, which gives it activity against anaerobic bacteria and protozoa.

Atrophic vaginitis is driven by estrogen deficiency after menopause, not by anaerobic or protozoal infection. The two conditions therefore share no plausible mechanistic link. The very high TxGNN score (0.997) is a graph-based result. It probably reflects the drug's proximity to other vaginal conditions in the knowledge graph rather than a real therapeutic mechanism.

Other predicted indications for secnidazole have far more support, especially bacterial vaginosis-related vaginal discharge and trichomonal vulvovaginitis. Both are infectious, mechanistically coherent, and supported by completed Phase 3 trials and RCTs. They are likely on-label uses rather than true repurposing, and their labels should be checked against the current Solosec label. They are outside the scope of this report, which covers the top-ranked prediction.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|------|
| NDA209363 | Solosec | Granule | Evofem Inc. |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction is supported only by the model score, with no trials, no literature, and no plausible mechanism. Atrophic vaginitis is an estrogen-deficiency condition that an antimicrobial is unlikely to treat.

**To proceed, the following is needed:**
- Any independent clinical or preclinical evidence for secnidazole in atrophic vaginitis (none found)
- A mechanistic rationale that does not depend on the graph-based score alone
- Package insert warnings and contraindications (a blocking data gap)
- Mechanism of action data from DrugBank
- Verification of the current US label indications
- Consideration of the infection-related predictions (bacterial vaginosis-related discharge, trichomonal vulvovaginitis), which have much stronger evidence and could be evaluated separately, with the diagnosis confirmed first
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

